Article Text

Download PDFPDF

Surrogate endpoints in global health research: still searching for killer apps and silver bullets?
  1. Madhukar Pai1,
  2. Samuel G Schumacher2,
  3. Seye Abimbola3,4
  1. 1McGill Global Health Programs and McGill International TB Centre, McGill University, Montreal, Quebec, Canada
  2. 2Foundation for Innovative New Diagnostics, Geneva, Switzerland
  3. 3The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
  4. 4School of Public Health, University of Sydney, Sydney, New South Wales, Australia
  1. Correspondence to Dr Madhukar Pai; madhukar.pai{at}mcgill.ca

Statistics from Altmetric.com

In clinical research, there is widespread acceptance that surrogate endpoints may not translate to long-term benefits.1–3 Clinical epidemiologists highlight the hazards of surrogate measures (eg, biomarkers, laboratory test results and short-term improvements in health) that substitute for outcomes which are important for patients (eg, avoiding premature death or severe disability). For example, in cardiovascular research, improvements in parameters such as blood pressure or cholesterol may not improve outcomes such as deaths. Improvements in surrogate endpoints may not correlate with real outcomes of interest (and may even increase the risk of death, in some cases). And there are many examples and case studies in the literature that illustrate the hazards of using surrogates in clinical epidemiology.1–3

In comparison, in global health, we are often stunned when interventions that showed improvements in surrogate endpoints do not lead to lives being saved. Take, for example, the new tuberculosis (TB) detection technology, Xpert MTB/RIF(R) (Cepheid Inc, Sunnyvale, California, USA), an automated, molecular test for TB and drug resistance. Xpert MTB/RIF was first endorsed by WHO in 20104 and has since been rolled out in many countries with over 23 million tests conducted in the past 6 years.5 While the test is rapid, accurate and much superior to tests that have been in use for decades,6 some pragmatic randomised controlled trials (RCTs) did not show improvements in long-term outcomes such as reduction in mortality.7 8 These results have prompted media headlines such as ‘improved diagnostics fail to halt the rise of tuberculosis.”9

The recent RCT in India of the WHO Safe Childbirth Checklist presents another example. The WHO Safe Childbirth Checklist is a quality-improvement tool to promote systematic adherence to practices that have been associated with improved childbirth outcomes.10 In a large-scale study in 24 districts in India, adherence of birth attendants to …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.